Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04136309 · 1 trial · 1 indication
WOMAC: self-administered, disease-specific 24 item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness, and physical function in participants with osteoarthritis (OA) of the hip and/or knee. It consists of 3 domains: pain, stiffness and physical function. WOMAC pain domain consists of 5 questions scored on 5 point Likert scale (0=minimum pain to 4=maximum pain) where higher score indicates higher pain. It assesses amount of pain experienced due to OA in the study joint in past 48 hours. Total possible pain domain score calculated by addition of scores of each 5 questions ranged from: 0 (minimum) - 20 (maximum), higher scores indicate higher pain.
| Arm | Type | Description |
|---|---|---|
| PF-04136309 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04136309 | DRUG | 125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval. |
| Placebo | DRUG | Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309. |
Inclusion Criteria: * Male or female of any race, between the ages of 18 and 75 years inclusive * Female subjects must be of non-childbearing potential and have a negative pregnancy test at Screening. * Osteoarthritis of the knee of at least 6 months duration and meeting the American College of Rhe...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
PF-04136309 was studied for the treatment of osteoarthritic pain of the knee. It was evaluated in a Phase 2 clinical trial in adults with knee osteoarthritis. It is an investigational small molecule and is not an approved therapy for osteoarthritis or any other indication.
PF-04136309 was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 2 study of the compound in knee osteoarthritis. The program is a Pfizer musculoskeletal asset.
PF-04136309 reached Phase 2 clinical development. Its single recorded trial, NCT00689273, was a Phase 2 study in subjects with osteoarthritic pain of the knee, and that trial is completed. No active trials of PF-04136309 are ongoing, and the drug is not approved.
PF-04136309 was evaluated in one clinical trial, NCT00689273, titled a randomized, double-blind, placebo-controlled Phase 2 study in subjects with osteoarthritic pain of the knee. The trial enrolled 159 participants across the United States and South Korea and is completed.
NCT00689273 was a randomized, double-blind, placebo-controlled Phase 2 study of PF-04136309 in adults with osteoarthritic pain of the knee. It enrolled 159 participants aged 18 years and older of all sexes, across sites in the United States and South Korea, and did not select patients by biomarker.